Patents by Inventor Stuart Helfand

Stuart Helfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
    Patent number: 7419992
    Abstract: A method of treating angiogenesis-implicated disorders by selecting a subject predisposed to an angiogenesis-implicated disorder and then administering an effective amount of an endogenous aryl hydrocarbon receptor ligand or its analogs according to a formula as disclosed herein is disclosed.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: September 2, 2008
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Jiasheng Song, Stuart Helfand, Nasim Akhtar
  • Early Detection of Hemangiosarcoma and Angiosarcoma
    Publication number: 20080050730
    Abstract: A variety of methods, compositions and kits are provided for the early detection, diagnosis and treatment of hemangiosarcoma in dogs and angiosarcomas in humans.
    Type: Application
    Filed: September 9, 2005
    Publication date: February 28, 2008
    Applicant: Regents of the University of Colorado
    Inventors: Jaime Modiano, Stuart Helfand
  • Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
    Publication number: 20070043092
    Abstract: A method of treating angiogenesis-implicated disorders by selecting a subject predisposed to an angiogenesis-implicated disorder and then administering an effective amount of an endogenous aryl hydrocarbon receptor ligand or its analogs according to a formula as disclosed herein is disclosed.
    Type: Application
    Filed: April 10, 2006
    Publication date: February 22, 2007
    Inventors: Hector DeLuca, Margaret Clagett-Dame, Jiasheng Song, Stuart Helfand, Nasim Akhtar
  • Methods for targeting interleukin-12 to malignant endothelium
    Publication number: 20050063948
    Abstract: Fusion proteins containing a mammalian interleukin-12 operably linked to an RGD-containing peptide as well as nucleic acid sequences, vectors and host cells for expression of these fusion proteins are provided. Also provided are methods of using these fusion proteins to inhibit tumor growth and to decrease the toxicity associated with interleukin-12 administration.
    Type: Application
    Filed: August 13, 2004
    Publication date: March 24, 2005
    Inventors: Erin Dickerson, Stuart Helfand, Nasim Akhtar
  • Malignant endothelial cell line and uses thereof in models for angiogenesis
    Publication number: 20050054089
    Abstract: An immortalized hemangiosarcoma cell line of malignant canine endothelial cells which possesses surface expression characteristics and growth factor and cytokine expression profiles typical of nonmalignant activated endothelial cells is provided. In vitro and in vivo models for angiogenesis produced from this cell line as well as methods for identifying antiangiogenic agents using these models are also provided.
    Type: Application
    Filed: September 5, 2003
    Publication date: March 10, 2005
    Inventors: Stuart Helfand, Nasim Akhtar, Erin Dickerson, Marcia Padilla